XW0K3JA
Introduction Coronary Artery, Two Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Two Balloons, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | K Coronary Artery, Two Arteries |
| Approach | 3 Percutaneous |
| Device | J Paclitaxel-Coated Balloon Technology, Two Balloons |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Coronary Artery, Two Arteries
Two coronary arteries are targeted together for Introduction procedures under New Technology when a novel substance is delivered via catheter into a pair of coronary vessels during the same procedural episode, distinguishing this code from single-artery treatment. This scenario typically arises when a patient has disease or an indication affecting more than one coronary territory, requiring the same investigational or newly approved agent to be introduced into each affected artery. Because the coronary circulation is segmented into distinct territories supplying different regions of the myocardium, treating two arteries reflects a broader therapeutic intent than a single-vessel approach. Coding accuracy depends on confirming that exactly two coronary arteries, rather than one or three or more, received the introduced New Technology substance.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Paclitaxel-Coated Balloon Technology, Two Balloons
This value specifies use of paclitaxel-coated balloon angioplasty in which two balloons were used during the procedure to deliver antiproliferative drug coating to vessel walls while treating stenosis. It differs from the one-balloon and three- or four-or-more-balloon values purely by balloon count, reflecting greater procedural extent such as treatment of multiple lesions or vessel segments rather than a distinct device type.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.